Purastat and its role Upper GI bleeding

Purastat is an innovative and promising hemostatic agent specifically designed for the management of upper gastrointestinal bleeding (UGIB), particularly non-variceal UGIB. It is a synthetic peptide-based gel that belongs to the class of self-assembling peptide hydrogels. Its novel mechanism of action and clinical applications make it a valuable tool for addressing bleeding in challenging scenarios where conventional methods may fail.

### **Role of Purastat in Upper GI Bleeding:**

#### **Mechanism of Action:**

Purastat works by forming a nanofiber hydrogel when exposed to physiological conditions. This hydrogel provides multiple benefits at the bleeding site:

1. **Physical Hemostasis:** The hydrogel forms a physical barrier over the bleeding site, effectively preventing further blood loss and promoting clot formation.

2. **Platelet Aggregation:** It acts as a scaffold to facilitate platelet aggregation and stabilize clots.

3. **Mucosal Protection:** By covering the bleeding site, it protects the underlying tissue from further damage caused by gastric acid or mechanical forces, which aids in healing.

#### **Clinical Applications in UGIB:**

Purastat is primarily used in endoscopic procedures to manage **non-variceal upper gastrointestinal bleeding (NVUGIB)**. It has demonstrated efficacy in controlling bleeding from various causes, including:

1. **Peptic Ulcers:**

• Active bleeding from gastric or duodenal ulcers.
• Bleeding associated with adherent clots or visible blood vessels in ulcers.

2. **Post-Endoscopic Procedures:**

• Used as an adjunct to prevent rebleeding after interventions such as thermal coagulation or hemoclip application.

3. **Other Causes of UGIB:**

• Bleeding from malignancies, radiation-induced ulcers, or post-surgical sites.

#### **Advantages of Purastat in UGIB:**

1. **Ease of Application:**

• Purastat is delivered through an endoscope using a catheter, making it minimally invasive and easy to apply directly to the bleeding site.

2. **Rapid Hemostasis:**

• It has shown to quickly stop bleeding in challenging cases, even when conventional methods fail.

3. **Safety Profile:**

• Purastat is biocompatible and biodegradable, meaning it is well-tolerated without significant adverse effects. It has minimal systemic absorption, reducing the risk of systemic side effects.

4. **Potential for Prophylaxis:**

• Purastat has been explored for use in preventing bleeding in high-risk patients, such as those undergoing endoscopic procedures or with recurrent bleeding risks.

#### **Limitations:**

1. **Cost:**

• Purastat is relatively expensive compared to conventional hemostatic methods, which may limit its accessibility, especially in resource-limited settings.

2. **Limited Evidence Base:**

• While initial studies and trials have shown promising results, long-term data and large-scale randomized controlled trials are needed to fully establish its efficacy and cost-effectiveness.

3. **Restricted Indications:**

• Currently, Purastat is primarily used for non-variceal UGIB. Its role in managing **variceal bleeding** is not established.

### **Clinical Evidence:**

1. **Randomized Controlled Trials:** Studies have shown Purastat's effectiveness in achieving hemostasis in cases of non-variceal UGIB, particularly in peptic ulcers with active bleeding or stigmata of hemorrhage.

2. **Meta-Analyses:** Systematic reviews suggest that Purastat reduces the need for additional endoscopic interventions and lowers rebleeding rates when used as an adjunctive therapy.

3. **Real-World Applications:** Case reports and series highlight its successful use in refractory bleeding cases, such as bleeding from malignancies or other challenging lesions.

### **Clinical Guidelines:**

While Purastat is not yet universally included in major guidelines for UGIB management (e.g., ACG, ESGE, or ASGE), it is recognized as a promising adjunct for cases of refractory bleeding or when conventional methods fail. As more evidence emerges, it may become a standard part of UGIB management protocols.

### **Summary:**

Purastat represents a significant advancement in the management of UGIB, offering rapid and effective hemostasis in cases of non-variceal bleeding. Its innovative mechanism of action, ease of application, and favorable safety profile make it a valuable tool, especially for challenging or refractory cases. However, its high cost and limited evidence base remain barriers to widespread adoption. As more clinical trials and real-world studies are conducted, Purastat is likely to play an increasingly important role in UGIB management.

### **Key Takeaways:**

• **Indication:** Primarily used for non-variceal UGIB (e.g., peptic ulcer bleeding, post-endoscopic procedures).
• **Mechanism:** Self-assembling peptide hydrogel creates a physical barrier, facilitates clot stabilization, and protects the mucosa.
• **Advantages:** Rapid hemostasis, ease of use, biocompatibility, and low systemic side effects.
• **Limitations:** High cost and limited evidence compared to traditional methods.
• **Future Potential:** May be incorporated into clinical guidelines as more evidence emerges.

Purastat is an exciting development in the field of gastroenterology, offering hope for better outcomes in the management of upper gastrointestinal bleeding.